Sutimlimab in Cold Agglutinin Disease | Zendy

Alexander Röth | Zendy; Wilma Barcellini | Zendy; Shirley D’Sa | Zendy; Yoshitaka Miyakawa | Zendy; Catherine M. Broome | Zendy; Marc Michel | Zendy; David J. Kuter | Zendy; Bernd Jilma | Zendy; Tor Henrik Anderson Tvedt | Zendy; Joachim Fruebis | Zendy; Xiaoyu Jiang | Zendy; Stella Lin | Zendy; Caroline Reuter | Zendy; Jaime MoralesArias | Zendy; William E. Hobbs | Zendy; Sigbjørn Berentsen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sutimlimab in Cold Agglutinin Disease

Author(s) -

Alexander Röth,

Wilma Barcellini,

Shirley D’Sa,

Yoshitaka Miyakawa,

Catherine M. Broome,

Marc Michel,

David J. Kuter,

Bernd Jilma,

Tor Henrik Anderson Tvedt,

Joachim Fruebis,

Xiaoyu Jiang,

Stella Lin,

Caroline Reuter,

Jaime MoralesArias,

William E. Hobbs,

Sigbjørn Berentsen

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2027760

Subject(s) - cold agglutinin disease , autoimmune hemolytic anemia , hemolysis , cold agglutinin , complement system , serine protease , classical complement pathway , monoclonal antibody , immunology , antibody , medicine , protease , chemistry , biochemistry , enzyme

Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that is caused by activation of the classic complement pathway. Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this pathway.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research